Although CRP ASOs could reduce the plasma levels of CRP through inhibiting hepatic CRP synthesis, we failed to demonstrate any beneficial (antiatherogenic) effects caused by CRP lowering: CRP ASO treatment did not change the aortic and coronary atherosclerosis in two groups of WHHL rabbits compared with that of controls. The gene discussed is CRP; the disease is coronary atherosclerosis.